SOURCE: Micromet Inc.

October 30, 2006 03:05 ET

Micromet, Inc. to Host Conference Call and Live Webcast to Discuss Third Quarter 2006 Financial Results

CARLSBAD, CA -- (MARKET WIRE) -- October 30, 2006 --



Carlsbad, CA, - October 30, 2006 - Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, will host a conference call and live webcast on Thursday, November 9, 2006, at 09:00am Eastern Time (03:00pm Central European Time) to discuss the company's financial results for the third quarter ended September 30, 2006.

The conference call will be webcast simultaneously over the Internet. To listen, please visit Micromet's corporate website at www.micromet-inc.com. The webcast will be archived for one year. Alternatively, callers may participate in the conference call by dialing 866-831-6247 (domestic), +1-617-213-8856 (international) or +44-207-365-8426 (United Kingdom). The passcode for the conference call is MICROMET.

A replay of the call can be accessed by dialing 888-286-8010 (domestic), +1-617-801-6888 (international) or +44-207-3658427 (United Kingdom). The passcode for the replay is 39917814.



Contact Information

Investors: Ines-Regina Buth
(760) 494-4235 (US)
+49 (0)89 895277 221 (Europe)
ines.buth@micromet-inc.com

Media Europe: Evelyn Wolf
+49 (0)89 895277 220
evelyn.wolf@micromet-inc.com

Media US: Susan Noonan
(212) 966-3650
susan@sanoonan.com

About Micromet, Inc. (www.micromet-inc.com )

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. Two Phase 2 clinical trials for the treatment of patients with breast cancer and prostate cancer have been completed in Q3, 2006, with adecatumumab (MT201), a recombinant human monoclonal antibody. MT103 (MEDI-538), a BiTE® product candidate, is being studied in a Phase 1 clinical trial for the treatment of patients with Non Hodgkin Lymphoma. Micromet has established a drug development platform based on its BiTE® technology, a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Micromet has established collaborations with MedImmune, Inc. and Serono.






Copyright © Hugin ASA 2006. All rights reserved.

Contact Information